Kobe C Yuen
Overview
Explore the profile of Kobe C Yuen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
635
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Yuen K, Tran B, Anton A, Hamidi H, Costello A, Corcoran N, et al.
Prostate
. 2022 Apr;
82(9):993-1002.
PMID: 35435276
Background: Despite the rapidly evolving therapeutic landscape, immunotherapy has demonstrated limited activity in prostate cancer. A greater understanding of the molecular landscape, particularly the expression of immune-related pathways, will inform...
2.
Powles T, Yuen K, Gillessen S, Kadel 3rd E, Rathkopf D, Matsubara N, et al.
Nat Med
. 2022 Jan;
28(1):144-153.
PMID: 35013615
Early clinical data indicate that some patients with castration-resistant prostate cancer may benefit from program death ligand-1 (PD-L1) inhibition, especially with enzalutamide. The IMbassador250 trial (no. NCT03016312) enrolled 759 men...
3.
Yuen K
Bio Protoc
. 2021 Aug;
7(6):e2178.
PMID: 34458488
Protein kinase R (PKR) is one of the key RNA-activated sensors for innate immunity. PKR is activated by pathogenic or aberrant RNAs such as short double-stranded RNAs or those with...
4.
Powles T, Assaf Z, Davarpanah N, Banchereau R, Szabados B, Yuen K, et al.
Nature
. 2021 Jun;
595(7867):432-437.
PMID: 34135506
Minimally invasive approaches to detect residual disease after surgery are needed to identify patients with cancer who are at risk for metastatic relapse. Circulating tumour DNA (ctDNA) holds promise as...
5.
Fong L, Morris M, Sartor O, Higano C, Pagliaro L, Alva A, et al.
Clin Cancer Res
. 2021 Jun;
27(17):4746-4756.
PMID: 34108181
Purpose: Men with metastatic castration-resistant prostate cancer (mCRPC) have limited treatment options after progressing on hormonal therapy and chemotherapy. Here, we evaluate the safety and efficacy of atezolizumab (anti-PD-L1) +...
6.
Yuen K, Liu L, Gupta V, Madireddi S, Keerthivasan S, Li C, et al.
Nat Med
. 2021 Feb;
27(3):560.
PMID: 33547461
No abstract available.
7.
Yuen K, Liu L, Gupta V, Madireddi S, Keerthivasan S, Li C, et al.
Nat Med
. 2020 May;
26(5):693-698.
PMID: 32405063
Although elevated plasma interleukin-8 (pIL-8) has been associated with poor outcome to immune checkpoint blockade , this has not been comprehensively evaluated in large randomized studies. Here we analyzed circulating...
8.
Wagle M, Castillo J, Srinivasan S, Holcomb T, Yuen K, Kadel E, et al.
Cancer Immunol Res
. 2020 Apr;
8(7):844-850.
PMID: 32321776
Prostate cancer is the second leading cause of cancer-related death in men. Despite having a relatively lower tumor mutational burden than most tumor types, multiple gene fusions such as have...
9.
Yuen K, Gerton J
PLoS Genet
. 2018 Jan;
14(1):e1007118.
PMID: 29370184
Structural maintenance of chromosome (SMC) protein complexes, including cohesin and condensin, are increasingly being recognized for their important role in cancer and development, making it critical that we understand how...
10.
Yuen K, Slaughter B, Gerton J
Sci Adv
. 2017 Jul;
3(6):e1700191.
PMID: 28691095
Structural maintenance of chromosome complexes, such as cohesin, have been implicated in a wide variety of chromatin-dependent functions such as genome organization, replication, and gene expression. How these complexes find...